Henrik Stenqvist

Part of Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum GmbH engages in researching, developing, and innovating therapies that improve the lives of people with rare diseases. The company is based in Martinsried, Germany. The CEOs are Henrik Stenqvist, Thomas Trilling, Hege Hellstroem. The German company was founded in 2010.

Part of Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum Ltd. manufactures and sells drugs for rare diseases. The company is based in Cambridge, UK and was founded in 2002.

Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.